ZEB2 and cancer: While the behavior of ZEB2 and TWIST1/2 was not consistent across data sets, unlike these EMT factors, ZEB1 has significant dynamical changes at the M-end of EMT path in both normal and cancer cells, indicating its primary role in robustly controlling E-gene expression at this phase of canonical EMT.